Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SKP FlutiForm HFA pMDI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SKP FlutiForm HFA pMDI | DRUG | Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate. |
Inclusion Criteria: * 1\. Documented use of an inhaled corticosteroid for at least 4 weeks prior to the Day 1 (Baseline) visit and at a dose not greater than 500 mcg/day fluticasone propionate inhalation (or equivalent dose for other inhaled corticosteroids). Subjects who enroll in this study SKY20...
SKP FlutiForm HFA pMDI is an investigational small molecule being developed for the treatment of asthma. It is a pressurized metered-dose inhaler formulation studied in patients with moderate to severe asthma. As of the available data, it is in Phase 3 clinical development and is not yet approved by regulatory authorities.
SKP FlutiForm HFA pMDI is being developed by Abbott Laboratories, a company publicly traded under the ticker symbol ABT. The drug is currently in Phase 3 clinical development for asthma, and it remains investigational, meaning it has not yet received regulatory approval.
SKP FlutiForm HFA pMDI is in Phase 3 clinical development. It is being studied as a treatment for asthma in a completed Phase 3 trial. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
SKP FlutiForm HFA pMDI has one completed Phase 3 clinical trial registered under NCT00747318. This open-label continuation study enrolled 280 participants with moderate to severe asthma across the United States, Mexico, Peru, Romania, and Ukraine. The trial was not randomized or double-blinded and did not use a control group.
SKP FlutiForm HFA pMDI is the drug name used in the clinical trial record, and the trial title refers to it as FlutiForm HFA pMDI. The drug is being developed by Abbott Laboratories for asthma and is currently in Phase 3 clinical development.